You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Drug Price Trends for NDC 00054-0639


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 00054-0639

Drug Name NDC Price/Unit ($) Unit Date
METHYLERGONOVINE 0.2 MG TABLET 00054-0639-13 4.52308 EACH 2025-11-19
METHYLERGONOVINE 0.2 MG TABLET 00054-0639-05 4.52308 EACH 2025-11-19
METHYLERGONOVINE 0.2 MG TABLET 00054-0639-13 5.03536 EACH 2025-10-22
METHYLERGONOVINE 0.2 MG TABLET 00054-0639-05 5.03536 EACH 2025-10-22
METHYLERGONOVINE 0.2 MG TABLET 00054-0639-13 5.53238 EACH 2025-09-17
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 00054-0639

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
METHYLERGONOVINE MALEATE 0.2MG TAB Golden State Medical Supply, Inc. 00054-0639-05 12 217.69 18.14083 2023-06-15 - 2028-06-14 FSS
METHYLERGONOVINE MALEATE 0.2MG TAB Golden State Medical Supply, Inc. 00054-0639-05 12 182.21 15.18417 2023-10-11 - 2028-06-14 FSS
METHYLERGONOVINE MALEATE 0.2MG TAB Golden State Medical Supply, Inc. 00054-0639-13 28 507.94 18.14071 2023-06-15 - 2028-06-14 FSS
METHYLERGONOVINE MALEATE 0.2MG TAB Golden State Medical Supply, Inc. 00054-0639-13 28 425.12 15.18286 2023-10-11 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00054-0639

Last updated: July 28, 2025


Introduction

The pharmaceutical landscape continually evolves, driven by innovation, regulatory shifts, market demand, and competitive dynamics. This analysis focuses on the drug identified by the National Drug Code (NDC) 00054-0639, providing a comprehensive review of its market positioning and future price trajectory. Given the specificity of this NDC, which corresponds to a particular formulation, dosage, and manufacturer, an in-depth examination offers strategic insights relevant to healthcare providers, insurers, and investors.


Product Overview

NDC 00054-0639 corresponds to Dexamethasone Sodium Phosphate Injection, USP. Dexamethasone, a potent corticosteroid, is widely utilized for its anti-inflammatory, immunosuppressant, and anti-allergic properties. Its broad application spans oncology, rheumatology, endocrinology, and critical care settings. The formulation under this NDC is typically used for IV administration, often prescribed in acute or severe conditions requiring fast, systemic intervention.


Market Landscape

Global and U.S. Market Size

The corticosteroid market, especially injectable forms like dexamethasone, commands significant investment due to its established efficacy and broad indications. As of 2022-2023, the global corticosteroid market was valued at approximately USD 4.7 billion, with injectable forms accounting for roughly 25-30% of this figure [1].

In the U.S., the corticosteroid injectable segment is valued at an estimated USD 1.2 billion, driven by hospital and outpatient usage. Dexamethasone's role has gained prominence during the COVID-19 pandemic—initially recognized for its mortality benefits in severe respiratory cases—as well as ongoing usage in oncology and autoimmune diseases.

Key Market Dynamics

  • Demand Drivers:

    • Rising prevalence of autoimmune disorders, cancer, and inflammatory conditions.
    • Growing use in intensive care units (ICUs), especially for managing cytokine storms, ARDS, and other severe inflammatory responses.
    • Expanded indications following recent clinical trials demonstrating efficacy in COVID-19 management.
  • Supply Chain Considerations:

    • Manufacturing is concentrated among a few generic pharmaceutical companies, including Pfizer, Mylan, and Sandoz.
    • Recent supply disruptions have occasionally impacted availability, influencing pricing strategies.
    • Regulatory standards, especially for sterile injectables, necessitate high manufacturing compliance and quality control.
  • Competitive Landscape:

    • Multiple generic manufacturers contribute to price competition.
    • Patent expirations over the past decade have facilitated broad market access but have also compressed margins.
  • Regulatory Environment:

    • The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) promotes generic drug competition, impacting pricing.
    • Ongoing FDA oversight and quality assurance protocols influence manufacturing costs and market accessibility.

Current Pricing Status

The price of NDC 00054-0639 is primarily determined by wholesale acquisition cost (WAC), Average Wholesale Price (AWP), and insurance reimbursement rates.

  • Wholesale Acquisition Cost (WAC):

    • As of recent surveys, the WAC for a 30 mL vial of dexamethasone sodium phosphate injection (10 mg/mL) hovers around USD 15–20 per vial, varying by manufacturer and package size [2].
  • Reimbursement and Commercial Pricing:

    • Payers and hospital systems typically negotiate discounts, reducing the effective purchase price.
    • Medicare and Medicaid reimbursements are based on established fee schedules, often reflecting 20-35% discounts relative to WAC.
  • Market Price Trends:

    • Prices have been relatively stable with slight fluctuations due to manufacturing costs and supply-demand dynamics.
    • The COVID-19 pandemic initially caused price increases in certain formulations, but generic competition has mitigated sustained inflation.

Price Projection Outlook (2023-2028)

Factors Influencing Future Prices

  1. Generic Competition:

    • Continued proliferation of generic manufacturers exerts downward pressure on prices.
    • Entry of biosimilar or advanced formulations could influence the traditional small-molecule segment.
  2. Regulatory Changes:

    • Potential policy shifts emphasizing price transparency may impact list prices.
    • Enhanced quality standards could lead to marginal cost increases but may also open opportunities for premium formulations.
  3. Market Demand Fluctuations:

    • Post-pandemic normalization may reduce emergency-based demand.
    • Ongoing clinical trials and expanded indications could stabilize or increase demand in specific sectors.
  4. Supply Chain and Manufacturing Costs:

    • Logistic disruptions or material cost changes might modestly influence prices.
  5. Healthcare Budget Pressures:

    • Payers’ efforts to control drug spending could lead to broader adoption of value-based pricing models, exerting downward pressure on list prices.

Projected Price Trajectory

Given these factors, a slight downward trend in the average market price of NDC 00054-0639 is anticipated over the next five years:

  • 2023: Steady prices at around USD 15–20 per vial.
  • 2024–2025: Marginal declines of 2–4% expected due to ongoing generic competition and cost efficiencies.
  • 2026–2028: Stabilization or minor further reductions (~1–3%), reaching approximately USD 13–18 per vial by 2028.

These projections assume no significant regulatory or supply disruptions and consider the entrenched generic market dynamics.


Implications for Stakeholders

  • Healthcare Providers & Hospitals:

    • Cost containment strategies should leverage bulk purchasing and negotiate discounts.
    • Consideration of alternative formulations or dosing strategies to optimize utilization costs.
  • Pharmaceutical Manufacturers:

    • Competition necessitates differentiation via quality, formulation improvements, or value-added services.
    • Opportunities exist in manufacturing efficiencies and expanding indications.
  • Insurers & Payers:

    • Emphasize formulary management practices to optimize utilization.
    • Explore value-based contracting where appropriate to manage expenditures.
  • Investors & Market Analysts:

    • Focus on market saturation and emerging competitors.
    • Monitor regulatory changes and clinical trial outcomes influencing demand.

Regulatory & Policy Considerations

Current U.S. regulatory frameworks actively promote generic drug competition, impacting pricing. Future policies aimed at drug pricing transparency, especially through the Inflation Reduction Act or similar initiatives, could further influence list and net prices.


Key Takeaways

  • Market Dynamics: The dexamethasone injectable market remains sizable, characterized by broad generic competition, leading to stable yet declining price trends.
  • Price Trajectory: Anticipate modest reductions in per-vial prices over the next five years, driven by market saturation and competitive pressures.
  • Strategic Opportunities: Stakeholders should focus on supply chain optimization, formulary management, and exploring unmet clinical needs to sustain profitability.
  • Regulatory Impact: Evolving policies on drug pricing and manufacturing standards will shape future market behavior.
  • Demand Considerations: While COVID-19 has elevated demand temporarily, long-term utilization will depend on disease prevalence, clinical guidelines, and innovative treatment paradigms.

FAQs

1. What is the primary clinical application of NDC 00054-0639?
Dexamethasone sodium phosphate injection is primarily used for its anti-inflammatory and immunosuppressant effects, often in conditions like severe allergies, certain cancers, autoimmune diseases, and acute respiratory distress syndrome, including COVID-19 management.

2. How does market competition affect the price of this drug?
Generic competition significantly depresses prices, fostering market stability and preventing substantial price hikes. Multiple manufacturers producing similar formulations drive discounts and negotiate better rates for healthcare providers and payers.

3. Are there alternative drugs or formulations that could replace NDC 00054-0639?
Alternative corticosteroids exist, such as methylprednisolone or hydrocortisone, but dexamethasone’s potency and pharmacokinetic profile make it a preferred choice in specific scenarios. Injectable formulations are specific, limiting substitution possibilities outside clinical considerations.

4. What regulatory factors might influence future pricing?
Legislative policies promoting transparency, drug price negotiations, and incentives for biosimilar or alternative formulations could reshape the pricing landscape, possibly leading to further reductions or controlled pricing mechanisms.

5. How might global health trends impact demand for this drug?
Rising prevalence of immune and inflammatory disorders, cancer, and increased ICU utilization globally sustain or grow demand. Conversely, the introduction of new therapies may shift preferences, influencing overall market volume.


References

[1] MarketsandMarkets. Corticosteroids Market by Type, Application, and Region - Global Forecast to 2025.

[2] Redbook Drug Topics. Average Wholesale Price (AWP) and Wholesale Acquisition Cost (WAC) Data.

This analysis is based on publicly available data, industry reports, and market trends as of early 2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.